BIO 2020: IP’s vital role in COVID-19 fight, potential ‘chaos’ of pooling

Concerns that IP is hindering the development of tools to fight the COVID-19 are unfounded, and now is the time that we need IP the most, according to big pharma representatives.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Medtech

Senator calls on Biden to reject COVID IP waiver

2 March 2021 Thom Tillis, ranking member of the senate IP subcommittee, has urged US president Joe Biden to oppose ‘harmful’ proposals to waive rights related to COVID-19 vaccines currently in discussions at the World Trade Organisation.

Big Pharma

Quercis licenses patents for thromboembolism platform

28 January 2021 Biopharmaceutical company, Quercis Pharma, has exclusively licensed two patents to enhance its ability to provide approved treatments for COVID-19 and cancer.

Big Pharma

South Africa, India urge WTO to waive IP for COVID-19 treatments

8 October 2020 South Africa and India have asked the World Trade Organization to cede some stipulations governing IP so that treatments to combat COVID-19 can become more widely available, particularly in low-income countries.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

BIO 2020: IP’s vital role in COVID-19 fight, potential ‘chaos’ of pooling

More on this story

Editor's picks

Editor's picks

More features